Regulatory and Case Analysis of Long-Term Follow-Up for Advanced Therapy Medicinal Products Based on the European Medicines Agency Post-Authorisation Safety Study

Key Points

• The aim is to evaluate regulatory frameworks and long-term follow-up practices for advanced therapy medicinal products.
• Conducted a case analysis of existing post-authorisation safety studies.
• Reviewed regulatory guidelines provided by the European Medicines Agency.
• Analyzed data regarding the implementation and effectiveness of long-term follow-ups.
• Identified gaps in current long-term follow-up practices.
• Proposed recommendations for enhancing safety monitoring.
• Highlighted the importance of timely data collection for risk management.